Likes Subject
You gots me CONFUSED, Young Lady!! YES, I Invest-in-America 10/12/22 10:34 AM
you already posted there silly, so i replied gail 10/12/22 10:26 AM
O.K., I'll take a look at THAT one Invest-in-America 10/12/22 10:24 AM
i found it on my… gail 10/12/22 10:14 AM
ABEO: It's pronounced like, " ABALONE " (that Fish t Invest-in-America 10/12/22 10:12 AM
can anyone pronounce … gail 10/12/22 8:42 AM
nice pop in overnight trading. lets see what gail 10/12/22 7:43 AM
quiet board but this stock is on the gail 10/11/22 11:20 AM
$3.69 news data coming within a month stock1ace1 10/04/22 8:48 AM
Topline data from the Phase 3 VIITAL™ study stock1ace1 09/30/22 3:52 PM
Buying $3.01 phase 3 data due anyday 3 stock1ace1 09/30/22 3:52 PM
We need to get this over $1 INFINITI 06/21/22 6:18 PM
Let’s goooo$$$$ INFINITI 06/21/22 12:32 PM
Looks good here INFINITI 06/21/22 6:58 AM
ABEO .35 +7% saj 04/05/22 12:03 PM
* * $ABEO Video Chart 02-25-2021 * * ClayTrader 02/25/21 6:30 PM
They are MBIO, SIOX, and GTHX. GTHX will jerseyboy 02/25/21 1:33 PM
Which are those 3? CyrusDaVirus 02/25/21 1:07 PM
I had to say goodbye to Abeona earlier jerseyboy 02/12/21 6:48 PM
I like what they're doing and obviously also jerseyboy 02/03/21 6:24 PM
Apparently from the news today Michael Amoroso does jerseyboy 01/25/21 4:39 PM
Heck ya $$ Golden Cross $$ 01/22/21 8:33 PM
The share price is certainly showing a nice jerseyboy 01/22/21 5:26 PM
Chart looks to be a nice steady incline here $$ Golden Cross $$ 01/15/21 3:01 AM
With today's advance, this has almost doubled from jerseyboy 01/15/21 12:15 AM
strong chart here $$ Golden Cross $$ 01/12/21 10:15 AM
I feel like people are sleeping on this jerseyboy 12/21/20 5:44 PM
News just out spiking up on it railrider 12/21/20 12:21 PM
Wow - nice jump today - up 17%! jerseyboy 11/27/20 10:30 PM
Nice jump today and up over 50% from jerseyboy 11/27/20 10:15 AM
* * $ABEO Video Chart 11-11-2020 * * ClayTrader 11/11/20 6:11 PM
Breaking News: $ABEO What Are The Best Penny whytestocks 11/11/20 5:15 PM
2x813008 shares free options for 1 year, to realfast95 10/13/20 6:44 PM
On September 17, 2020, Abeona Therapeutics Inc. (the realfast95 10/07/20 7:55 AM
BREAKING NEWS: $ABEO Abeona Therapeutics' Board of Directors whytestocks 10/06/20 5:00 PM
Steven Rouhandeh realfast95 10/06/20 4:18 PM
Abeona Therapeutics’ Board of Directors Forms Special Committee realfast95 10/06/20 4:15 PM
Abeona Therapeutics selloff yesterday an overreaction, says B. realfast95 09/29/20 12:02 PM
picked up some shares for a bounce here RJ Trotts 09/28/20 1:37 PM
The rats are leaving a burning ship. willlbone 09/28/20 12:48 PM
Press Release: Abeona Therapeutics Announces Leadership and Board Transitions realfast95 09/28/20 9:33 AM barnyarddog 08/01/20 5:58 PM
News: $ABEO Abeona Therapeutics Reinitiates Enrollment in EB-101 whytestocks 07/08/20 7:45 AM
* * $ABEO Video Chart 05-11-2020 * * ClayTrader 05/11/20 6:19 PM
* * $ABEO Video Chart 03-17-2020 * * ClayTrader 03/17/20 6:08 PM
* * $ABEO Video Chart 02-19-2020 * * ClayTrader 02/19/20 6:00 PM
* * $ABEO Video Chart 02-12-2020 * * ClayTrader 02/12/20 5:06 PM
* * $ABEO Video Chart 02-11-2020 * * ClayTrader 02/11/20 6:16 PM
* * $ABEO Video Chart 02-10-2020 * * ClayTrader 02/10/20 5:29 PM
Abeona Therapeutics (NASDAQ:ABEO)‘s stock had its “buy” rating stockguard 01/14/20 3:02 PM
Likes Subject

10/12/22 10:34 AM
10/12/22 10:24 AM
10/12/22 10:14 AM
10/12/22 10:12 AM
10/12/22 8:42 AM
10/11/22 11:20 AM
10/04/22 8:48 AM
09/30/22 3:52 PM
09/30/22 3:52 PM
06/21/22 6:18 PM
06/21/22 12:32 PM
06/21/22 6:58 AM
04/05/22 12:03 PM
02/25/21 6:30 PM
02/25/21 1:33 PM
02/25/21 1:07 PM
02/12/21 6:48 PM
$$ Golden Cross $$
01/22/21 8:33 PM
01/22/21 5:26 PM
$$ Golden Cross $$
01/15/21 3:01 AM
$$ Golden Cross $$
01/12/21 10:15 AM
12/21/20 5:44 PM
12/21/20 12:21 PM
11/27/20 10:30 PM
11/27/20 10:15 AM
11/11/20 6:11 PM
11/11/20 5:15 PM
10/13/20 6:44 PM
10/06/20 4:18 PM
RJ Trotts
09/28/20 1:37 PM
09/28/20 12:48 PM
05/11/20 6:19 PM
03/17/20 6:08 PM
02/19/20 6:00 PM
02/12/20 5:06 PM
02/11/20 6:16 PM
02/10/20 5:29 PM

Abeona Therapeutics (ABEO)

Posts (Today)
Posts (Total)


Web Site:


Abeona Therapeutics Announces Fourth Quarter and Full Year 2015 Summary Financial Results and Recent Operational Highlights

NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 03/08/16 --  Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced summary financial results for the fourth quarter and full fiscal year ended December 31, 2015. The Company will provide a business update for investors and other stakeholders on a conference call, Wednesday, March 9th, at 4:45 pm (Eastern). Tim Miller, Ph.D., President and CEO and Jeffrey Davis, Chief Operating Officer, together with other executives, will conduct the call. Interested parties are invited to participate in the call by dialing 877-269-7756 (toll free domestic) or 201-689-7817 (international). The call will consist of an overview of the Company's 4Q15 financials, and a discussion of business highlights.

"The past year has led to significant advancements in our goal of building a leadership position in the field of gene therapy and plasma protein therapies towards transforming the lives of patients with rare diseases," stated Steven H. Rouhandeh, Executive Chairman. "In 2015, we expanded our pipeline with two clinical stage AAV gene therapies for Sanfilippo syndrome types A and B, added a third AAV gene therapy product in Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) (also known as juvenile Batten disease), signed a license to an innovative CRISPR-Cas9 gene editing platform in rare blood disorders, with an initial focus in Fanconi anemia, strengthened our team, and added substantial financial resources to our balance sheet. In 2016, our priorities include driving our AAV gene therapy and alpha-1 protease inhibitor programs into the clinic, and advancing our gene editing programs including defining of regulatory pathways to bring our CRISPR product candidates to patients."

Tim Miller, Ph.D., President and CEO, stated, "2016 will be an exciting, transformative year for Abeona Therapeutics as we position ourselves to enter multiple human clinical trials with our pipeline of innovative product candidates. As recently announced, the FDA allowance of the IND for the Phase 1/2 clinical study of ABO-102 for patients with Sanfilippo syndrome type A (MPS IIIA) moves our programs into the clinic here in the US, and we look forward to working with our collaborators to expand this program into Europe and Australia later this year. We believe that our gene therapy programs in Sanfilippo syndrome type B (ABO-101) and Juvenile Neuronal Ceroid Lipofuscinosis (ABO-201) will follow shortly. Lastly, we would like to thank our dedicated researchers and clinical collaborators, as well as the many dedicated patient foundations, for their tireless efforts and commitment to advancing new treatment options for these devastating unmet medical needs."

Recent Abeona Highlights

  • Sanfilippo syndrome gene therapy programs: On February 29, 2016, Abeona announced the FDA allowance of an Investigational New Drug (IND) for systemic AAV Phase 1/2 clinical study with ABO-102 gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). On January 11, 2016, we announced that initial regulatory approvals from European bodies -- the Genetically Modified Organism (GMO) Voluntary Release regulatory filings, and the ethical committee regulatory filings -- for both the ABO-101 and ABO-102 programs in Spain. Abeona plans to commence both programs for the upcoming human clinical trials to be conducted at Cruces University Hospital in Bilbao, Spain. Both the ABO-101 and ABO-102 programs have received Orphan Drug and Pediatric Rare Disease designations from the FDA.
    SDF-Alpha plasma protein program: Abeona has completed optimization of the downstream chromatography steps for our SDF-Alpha™ (alpha-1 protease inhibitor) for inherited COPD. Additional provisional patent applications have been filed to provide the Company with expanded intellectual property protection. The Company has expanded its CMO relationships to ensure it has the ability to manufacture clinical material for future trials. The Company confirms that its proprietary SDF platform provides significantly enhanced yields of alpha-1 protease inhibitor, at levels up to 10 times of that achievable with the industry standard Cohn processes, and with purity levels consistent with that achieved by other commercial processes.
    Advanced pipeline programs: Together with its academic collaborators, the Company continued to progress its pre-clinical programs in juvenile Batten disease and its CRISPR-Cas9 program in Fanconi anemia (FA) and other rare blood disorders. Juvenile Batten disease is the most common form of a group of disorders known as neuronal ceriod lipofuscinosis (NCL), a lysosomal storage disease that affects the nervous system in children and for which there are no approved treatment options. Fanconi anemia is a rare pediatric blood disease characterized by multiple physical abnormalities, bone marrow failure and a higher than normal risk of cancer. 
Most Liked Posts
(Last 30 Days)
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Most Liked Posts
(Last 30 Days)
New Post